Document:

EXHIBIT 10.5

 

AMENDMENT NO. 08 TO LOAN AND
SECURITY AGREEMENT

 

This AMENDMENT NO. 08 this (“Amendment 08”) is entered into as of August 13,
2010 by LIGHTHOUSE CAPITAL PARTNERS V, L.P. (“Lender”) and ARYx
THERAPEUTICS, INC., a Delaware corporation (“Borrower”) with reference to the following:

 

RECITALS

 

WHEREAS, Borrower and Lender have previously entered into that certain
Loan and Security Agreement No. 4521 dated as of March 28, 2005 (as
amended to date, the “Loan and Security
Agreement”; all initially capitalized terms not otherwise defined
herein shall have the meanings given to such terms in the Loan and Security
Agreement) together with the other agreements and instruments entered into in
connection therewith (collectively, the “Loan Documents”); and

 

WHEREAS,
Lender has made advances in the amount of $10,000,000, pursuant to Secured
Promissory Notes dated September 30, 2005 and December 30, 2005,
respectively, which Notes were subsequently amended and restated by that
certain Amended and Restated Secured Promissory Note dated October 1, 2008
(the “Commitment One Note”); and

 

WHEREAS, Lender has made advances in the amount of $9,000,000, pursuant
to a Secured Promissory Note dated February 29. 2008, which Note was
subsequently amended and restated by that certain Amended and Restated Secured
Promissory Note dated October 1, 2008 (“Commitment
Two Note”); and

 

WHEREAS, Borrower has requested that Lender make
additional modifications to the repayment terms of the Commitment One Note and
the Commitment Two Note; and

 

WHEREAS, Borrower has requested that Lender make
modifications to its security interest to accommodate a $4 million bridge loan
drawable in two equal tranches of $2 million (the “Bridge Loan”);
and

 

WHEREAS, Borrower has requested and Lender has agreed
to further modifications to the terms of the Loan Documents subject to the
satisfactory occurrence of certain conditions precedent as set forth below;

 

NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants herein contained, the parties hereby agree to modify the Loan and
Security Agreement and to perform such other covenants and conditions as
follows:

 

I.              Section 1.1,
the following definitions shall be added to the Loan and Security
Agreement:

 

“Amendment No. 08” means this Amendment No. 08 to
Loan and Security Agreement by and between Lender and Borrower.

 

“Bridge Debt Security Interest” means the security
interest  in favor of Bridge Lender to
the extent it secures Borrower’s obligations with respect to the Eligible
Bridge Debt.

 

“Bridge Lender” means MPM BioVentures and Ayer Capital
jointly and severally.

 

“Bridge Note” means any promissory note issued by Borrower
pursuant to the terms of the Bridge Note Agreement.

 

 

‘Bridge Note Agreement” means the Secured Note and Warrant
Purchase Agreement dated as of August 13, 2010 between Borrower and Bridge
Lender.

 

‘Bridge Note Security Agreement” means the Security Agreement
dated as of August 13, 2010 between Borrower and Bridge Lender pursuant to
which Borrower grants Bridge Lender a security interest in its assets to secure
its repayment obligations under the Bridge Notes.

 

“Commitment Three” means $1,696,972.97, provided, however,
Commitment Three shall be increased by $296,972.97, following payment by
Borrower of the August 2010 Schedule Payment under the Commitment Two Note
and provided further, Commitment Three shall be increased by an additional
$296,972.97, following payment by Borrower of the September 2010 Schedule
Payment under the Commitment Two Note, for a total not to exceed $2,290,918.91.

 

“Commitment Three Secured Promissory Note” means a note in
substantially the form of Exhibit B-4 to the Amendment 08.

 

“Eligible Bridge Debt” means the indebtedness due the Bridge
Lender pursuant to the Secured Promissory Notes issued to the Bridge Lenders
pursuant to the {Secured Note and Warrant Agreement dated as of August 13,
2010 (the “Bridge Note Agreement”); provided that
such indebtedness shall in no event exceed the lesser of (i) US$4,000,000.00  plus interest accruing at the rate of 12% per
annum and (ii) the unpaid portion of the amounts actually paid by Borrower
to Bridge Lender pursuant to the Bridge Note Agreement.

 

“Intercreditor Agreement” means the duly executed and
delivered Intercreditor Agreement between Lender and Bridge Lender in the form
of Exhibit III.

 

“New Value Obligations” means all indebtedness due (i) under
the Commitment Three Secured Promissory Note; (ii) all loans, advances,
and other financial accommodations provided to Borrower by Lender after August 13,
2010; (iii) all interest accruing on the foregoing; and (iv) all
Legal Expenses, attorneys Fees and other costs and charges incurred by Lender
in enforcing its rights or preserving the Collateral in connection with any of
the foregoing.

 

“Qualifying Transaction” means a collaboration partnership or
recapitalization of the Borrower, in either case, providing Borrower with at
least $40,000,000 in net cash proceeds (less conversion of the Bridge Loan),
that occurs before December 31, 2010.

 

“Security Agreement” means the Intellectual Property Security
Agreement in the form attached hereto as Exhibit II.

 

II.            Section 1.1,
each of  the following
definitions of the Loan and Security Agreement shall be deleted in its entirety
and replaced with the following:

 

“Collateral” includes, without
limitation, Exhibit I to this Amendment 08.  Without limiting the rights of and grants to
Lender under the Loan and Security Agreement, Borrower reaffirms its grant of a
security interest to Lender in all Collateral to secure all Obligations.

 

III.           Negative
Pledge.   Subject to Section 4.1.4, added under
Clause V of this Amendment, the Negative Pledge Agreement dated March 28,
2005, is terminated effective with the execution of this Amendment 08.

 

 

IV.           Sections
3.3, 3.4 and 3.5, shall be added to the
Loan and Security Agreement as follows:

 

3.3 Conditions to Initial Advance Under Commitment Three.  Lender shall make Advances to Borrower under
Commitment Three, subject to satisfaction of the conditions in Sections 3.3,
3.4 and 3.5.  The initial Advance under
Commitment Three of $1,696,972.97 is conditioned on each of the following: (i) Borrower
shall have received the first tranche of the Bridge Loan, (ii) Borrower
shall have provided Lender with a first priority security interest in all of
its tangible and intangible assets, including intellectual property, (iii) Borrower
shall have paid to Lender the Final Payment and Restructure Fee due under the
Commitment One Note and (iv) Borrower shall have paid Lender the July 2010
Scheduled Payment due under the Commitment Two Note.

 

3.4 Conditions to Second Advance Under Commitment Three. The second
Advance under Commitment Three of $296,972.97 is conditioned on Borrower having
paid to Lender the August 2010 Scheduled Payment due under the Commitment
Two Note.

 

3.5 Conditions to Final Advance Under Commitment Three. The final
Advance under Commitment Three of $296,972.97 is conditioned on Borrower having
paid to Lender the September 2010 Scheduled Payment due under the
Commitment Two Note.

 

V.            Sections
4.1.1, 4.1.2 , 4.1.3 and 4.1.4,
shall be added to the Loan and Security Agreement as follows:

 

4.1. Grant of Security Interests.

 

4.1.1. First Senior Security Interest.  Borrower grants to Lender a valid, first
priority, continuing security interest in all present and future Collateral in
order to secure prompt, full, faithful and timely payment and performance of
the New Value Obligations.

 

4.1.2. Third Senior Security Interest.  Borrower grants to Lender a valid, first
priority( subject only to the Bridge Debt Security Interest), continuing
security interest in all present and future Collateral in order to secure
prompt, full, faithful and timely payment and performance of the Obligations.

 

4.1.3. Recording Priority. Lender will file separate
but identical UCC financing statements to further perfect the security
interests granted pursuant to 4.1.1 and 4.1.2 Loan and Security Agreement as
such may be amended form time to time, and the UCC financing statement filed
first in time in connection with this Amendment No. 8 shall for all
purposes perfect the security interest granted pursuant to Section 4.1.1
hereof.

 

4.1.4
IP Release.  Upon the occurrence of a
Qualifying Transaction, Collateral shall consist of the property described on Exhibit I-A,
and Lender shall take such steps as Borrower reasonably requests to terminate
any Intellectual Property Security Agreement and release intellectual property
from the Collateral, provided (i) an Event of Default has not occurred and
is then continuing (ii) Bridge Lender releases such intellectual property
from its collateral and terminates any Intellectual Property Security Agreement
for its benefit, and (iii) no other person or entity then has a security
interest in the intellectual property being released.  Immediately upon such release, the Negative
Pledge Agreement dated March 28, 2005 shall be reinstated, and shall
thereafter be in full force and effect.

 

VI.           Article 8 of the Loan
and Security Agreement is deleted in its entirety and replaced with the
following:

 

 

“8.          EVENTS OF DEFAULT

 

Any
one or more of the following shall constitute an Event of Default by Borrower
hereunder:

 

8.1          Payment.  Borrower fails to pay within 1 business day
of the date when due and payable in accordance with the Loan Documents any portion
of the Obligations, or cancels an ACH payment or transfer Lender has initiated
in conformity with the terms hereof, provided,
however, that an Event of Default shall not occur on account of a
failure to pay due solely to an administrative or operational error if Borrower
had the funds to make the payment when due and makes the payment the business
day following Borrower’s knowledge of such failure to pay.

 

8.2          Certain Covenant Defaults.  Borrower fails to perform any obligation
under Section 6.5 or 6.6, or violates any of the covenants
contained in Section 7.

 

8.3          Other Covenant Defaults.  Borrower fails or neglects to perform, keep,
or observe any other term, provision, condition, covenant, or agreement
contained in this Agreement, in any of the other Loan Documents, or in any
other present or future agreement between Borrower and Lender and has failed to
cure such failure within 30 days after its occurrence.

 

8.4          Attachment.  Any material portion of Borrower’s assets is
attached, seized, subjected to a government levy, lien, writ or distress
warrant, or comes into the possession of any trustee or receiver and the same
is not returned, removed, waived, stayed, discharged or rescinded within 15
days.

 

8.5          Other Agreements.  There is a default in any agreement after the
expiration of any applicable cure periods to which Borrower is a party
resulting in a right by a third party, whether or not exercised, to accelerate
the maturity of any Indebtedness in excess of $100,000.

 

8.6          Judgments.  One or more judgments for an aggregate of at
least $100,000 is rendered against Borrower and remains unsatisfied and
unstayed for more than 30 days.

 

8.7          Injunction.  Borrower is enjoined,
restrained, or in any way prevented by court order from continuing to conduct
any material part of its business affairs, or if a judgment or other claim
becomes a Lien upon any material portion of Borrower’s assets.

 

8.8          Misrepresentation.  Any representation, statement, or report made
to Lender by Borrower or any Responsible Officer or authorized officer,
employee, agent, or director of Borrower purporting to speak on behalf of
Borrower was false or intentionally misleading in any material respect when
made.

 

8.9          Enforceability.  Lender’s ability to enforce its rights
against Borrower or any Collateral is impaired in any material respect, or
Borrower asserts that any Loan Document is not a legal, valid and binding
obligation of Borrower enforceable in accordance with its terms, or any
subordinating creditor breaches or purports to rescind or terminate its
agreement with Lender.

 

8.10        Involuntary Bankruptcy.  An involuntary bankruptcy case remains
undismissed or unstayed for 30 days or, if earlier, an order granting the
relief sought is entered.

 

8.11        Voluntary Bankruptcy or
Insolvency.  Borrower
commences a voluntary case under applicable bankruptcy or insolvency law,
consents to the entry of an order for relief in an involuntary case under any
such law, or consents or is subject to the appointment of or taking possession
by a receiver, liquidator, assignee, trustee, custodian or other similar
official of Borrower or any substantial part of its property, or makes an
assignment for the benefit of creditors, or fails generally or admits in
writing to its inability to pay its debts as they become due, or takes any
corporate action in furtherance of any of the foregoing.

 

8.12        Merger without Assumption. Borrower is
acquired by or merges into any other business entity, and such acquirer or
resulting entity either: (i) does
not provide an unconditional, unlimited guaranty of the Obligations in 

 

 

form
and substance satisfactory to Lender or (ii) is
of a credit quality unacceptable to Lender in its commercially reasonable
judgment.

 

8.13        Default under a Bridge Notes. Any default
under any Bridge Note.

 

8.14        Modification of Bridge Loan
Documentation. Any modification of the terms of a Bridge Note, the
Bridge Note Agreement, the Bridge Note Security Agreement or any other
agreements entered into or instruments issued in connection with the foregoing.

 

8.15        Acceleration of Bridge Note
Principal. The acceleration of the maturity of any portion of
the principal due under any Bridge Note.

 

8.16        Non-Occurrence of Second Closing. The Bridge
Lenders fail to purchase Bridge Notes in an aggregate principal amount of
US$4,000,000 by October 1, 2010.

 

8.17        Assignment of Bridge Notes. Any Bridge
Lender assigns, transfers or encumbers any rights arising under any Bridge
Note, the Bridge Note Agreement, the Bridge Note Security Agreement or any
other agreements entered into or instruments issued in connection with the
foregoing without the prior written consent of Lender, which consent shall not
be unreasonably withheld.

 

VI.           Conditions Precedent to the effectiveness of
Amendment 08:

 

The obligation of Lender to make any Advances pursuant to Commitment
Three is subject to each and every of the following conditions precedent in
form and substance satisfactory to lender in its sole discretion:

 

(a)           This
Amendment duly executed by Borrower.

 

(b)           An Intercreditor Agreement
in the form of Exhibit III duly executed and delivered by each of Lender
and the Bridge Loan note holders.

 

(c)           Borrower shall have
delivered a duly executed IP Security Agreement.

 

(d)           Without limiting the
foregoing or Lender’s rights or Borrower’s obligations under the Loan and
Security Agreement, such consents, amendments, filings, recordations, or other
documents from any persons or entities necessary to maintain the perfection and
priority of Lender’s security interest in the Collateral, in form and substance
satisfactory to Lender in its sole discretion.

 

(e)           All necessary
consents of shareholders, members, and other third parties with respect to the
execution, delivery and performance of this Agreement, Amendment 07, the
Restructure Warrant, and the other Loan Documents.

 

(f)            Borrower shall
have received the first tranche of the Bridge Loan, (ii) Borrower shall
have paid to Lender the Final Payment and Restructure Fee due under the
Commitment One Note and (iii) Borrower shall have paid Lender the July 2010
Scheduled Payment due under the Commitment Two Note.

 

VII.         Additional
Terms and Conditions

 

1.             Expenses.  Borrower shall pay reasonable fees and
expenses incurred by Lender’s legal counsel in connection with the preparation
and negotiation of documentation related to this Amendment 08 in an amount not
to exceed $17,500.  Such expenses are due
and payable when billed.

 

 

2.             Representations
and Warranties of Borrower.  Borrower warrants and represents, as a
significant material inducement to Lender to enter hereinto, that: (i) no Events of Default have occurred and are continuing
that have not been disclosed to Lender by Borrower in writing; (ii) it is not and
has no reason to believe it may be named as a party to any judicial or
administrative proceeding, litigation or arbitration, and has not received any
communication from any person or entity (whether private or governmental)
threatening or indicating the same; and (iii) it is in full compliance
with the Loan Documents.

 

3.             Release.  Borrower for itself and for its agents,
partners, stockholders, employees and affiliates and its or their successors
and assigns hereby waives, releases and further discharges Lender and its and
their officers, directors, stockholders, partners, successors, assigns, agents
and employees of and from any and all manner of claims for damages at law or in
equity with respect to any matter occurring prior to the date hereof which
Borrower or such other releasing party may have had.  Borrower acknowledges that it has read and understands
that it has waived the provisions of California Civil Code Section 1542,
which states:  “A general release does
not extend to claims which the creditor does not know or suspect to exist in
his favor at the time of executing the release, which if known by him must have
materially affected his settlement with the debtor.”  Each provision of this release shall be
severable from every other provision when determining its legal enforceability.

 

4.             No Control.  Borrower warrants and represents, as a significant
material inducement to Lender to enter hereinto, that none of Lender nor any
affiliate, officer, director, employee, agent, or attorney of Lender, have at
any time, from Borrower’s date of formation through to the date hereof, (i) exercised
management or other control over the Borrower, (ii) exercised undue
influence over Borrower or any of its officers, employees or directors, (iii) made
any representation or warranty, express or implied, to any party on behalf of
Borrower, (iv) entered into any joint venture, agency relationship,
employment relationship, or partnership with Borrower, (v) directed or
instructed Borrower on the manner, method, amount, or identity of payee of any
payment made to any creditor of Borrower, and further, Borrower warrants and
represents that by entering hereinto with Lender has not, are not and will not
have engaged in any of the foregoing.

 

5.             Integration
Clause.  This Amendment 08 represents
and documents the entirety of the agreement and understanding of the parties hereto
with respect to its subject matter.  All
prior understandings, whether oral or written, other than the Loan Documents,
are hereby merged hereinto.  NEITHER THE LOAN AND SECURITY AGREEMENT NOR THIS
AMENDMENT 08 MAY BE MODIFIED EXCEPT BY A WRITING SIGNED BY LENDER AND
BORROWER.  Each provision
hereof shall be severable from every other provision when determining its legal
enforceability such that Lender’s rights and remedies under this Amendment 08
may be enforced to the maximum extent permitted under applicable law.  This Amendment 08 shall be binding upon, and
inure to the benefit of, each party’s respective permitted successors and
assigns.  This Amendment 08 may be
executed in counterpart originals, all of which, when taken together, shall
constitute one and the same original document. 
No provision of any other document between Lender and Borrower shall
limit the effectiveness hereof or the rights and remedies of Lender against
Borrower.  In the event of any
contradiction or inconsistency among the terms and conditions of this Amendment
08 or the other Loan Documents this Amendment 08 shall prevail.

 

6.  Lender waives any Event of
Default arising out of Borrower’s failure to make any payments due prior to the
date of this Amendment 08.  Lender has no
knowledge of the existence of any other Evetns of Default under the Loan
Documents.

 

Except as amended hereby, the Loan and Security Agreement remains
unmodified and unchanged.

 

 

	
  ARYx
  THERAPEUTICS, INC.

  	
   

  	
  LIGHTHOUSE
  CAPITAL PARTNERS V, L.P.

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  Paul Goddard, Ph.D.

  	
   

  	
  By:

  	
  LIGHTHOUSE
  MANAGEMENT PARTNERS V, L.L.C., its general partner

  
	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Paul
  Goddard, Ph.D.

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:
  

  	
  Chairman
  and Chief Executive Officer

  	
   

  	
  By:

  	
  /s/
  Thomas Conneely

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Thomas
  Conneely

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
  Vice
  President

  

 

 

EXHIBIT B-4

 

COMMITMENT
THREE SECURED PROMISSORY NOTE

 

[$                          ]

 

This
SECURED PROMISSORY NOTE (this “Note”)
is made August       , 2010, by ARYx THERAPEUTICS, INC. (“Borrower”) in favor of LIGHTHOUSE CAPITAL PARTNERS V, L.P. (collectively
with its assigns, “Lender”), and
its assigns (collectively, “Holder”)
pursuant to that certain Loan and Security Agreement No. 4521 between
Borrower and Lender dated March 28, 2005, as amended, (the “Loan Agreement”) with reference to the
following:

 

FOR
VALUE RECEIVED, Borrower promises to pay in lawful money of the United States,
to the order of Lender, at 500 Drake’s Landing Road, Greenbrae, California
94904, or such other place as Lender may from time to time designate (“Lender’s Office”), the principal sum of
[$                    ]
(the “Advance”), including interest on the
unpaid balance of the Advance at the Basic Rate, and all other amounts due or
to become due hereunder according to the terms hereof.   Capitalized terms used and not otherwise
defined herein are defined in the Loan Agreement.

 

“Basic Rate” means a per annum rate of interest equal to 13%.

 

“Maturity Date” means the earliest of (i) a
Default or Event of Default, (ii) a Liquidation Event, (iii) September 30,
2010, but only if Borrower has not drawn down the full second tranche of the
Bridge Loan by such date (v) December 31, 2010, if Borrower shall
have drawn the second tranche of the Bridge Loan or (vi) the first
business day 18 months after the close of a Qualifying Transaction.

 

1.             Repayment.  Borrower
shall pay principal and accrued interest due hereunder from the date hereof
through the date upon which this Note is paid in full pursuant to the terms of
this Note; provided. that commencing on the date of the closing of the
Qualifying Transaction, Borrower shall make equal monthly installment of
principal and interest calculated on an 18 month straight-line amortization
basis. On the Maturity Date, Borrower shall pay all unpaid principal, accrued
interest and other costs and charge due hereunder.

 

2.             Interest.  Interest not paid when due will, to the
maximum extent permitted under applicable law, become part of principal and
thereafter bear like interest as principal. 
Interest on outstanding principal will accrue at the Basic Rate, will be
compounded monthly.  All interest
computations shall be based on a 360-day year and actual days elapsed.  All Obligations not paid when due shall bear
interest at the Default Rate unless waived in writing by Lender.  All amounts paid hereunder will be applied to
the Obligations in Lender’s discretion and as provided in the Loan Agreement.

 

3.             Prepayment.

 

a.             Mandatory Prepayment Upon a Liquidation Event.  If a Liquidation Event shall occur, then
Borrower shall simultaneously with such Liquidation Event pay to Lender (i) the outstanding principal amount
of this Note plus accrued interest and, (ii) all
other sums, if any, that shall have become due and payable hereunder with
respect to this Note.

 

b.             Voluntary Prepayment.  Borrower may prepay the Note if and only if
Borrower pays to Lender (i) the
outstanding principal amount of this Note plus accrued interest and (ii) all other sums, if any, that
shall have become due and payable hereunder with respect to this Note.

 

4.             Collateral.  This Note is secured by the Collateral.

 

 

5.             Waivers.  Borrower, and all guarantors and endorsers of
this Note, regardless of the time, order or place of signing, hereby waive
notice, demand, presentment, protest, and notices of every kind, presentment
for the purpose of accelerating maturity, diligence in collection, and, to the
fullest extent permitted by law, all rights to plead any statute of limitations
as a defense to any action on this Note.

 

6.             Choice of
Law; Venue.  THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO
PRINCIPLES OF CONFLICTS OF LAW.   EACH OF
BORROWER AND LENDER HEREBY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS LOCATED IN THE CITY AND COUNTY OF SAN FRANCISCO, STATE OF
CALIFORNIA.  BORROWER AND LENDER EACH
HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF
ACTION BASED UPON OR ARISING OUT OF THIS NOTE. 
EACH PARTY FURTHER WAIVES ANY RIGHT TO CONSOLIDATE ANY ACTION IN WHICH A
JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT
BE OR HAS NOT BEEN WAIVED.

 

7.             Miscellaneous.  THIS NOTE MAY BE MODIFIED ONLY BY A
WRITING SIGNED BY BORROWER AND LENDER.  Each provision hereof is severable
from every other provision hereof and of the Loan Agreement when determining
its legal enforceability.  Sections and
subsections are titled for convenience, and not for construction.  “Hereof,” “herein,” “hereunder,” and similar
words refer to this Note in its entirety. 
“Or” is not necessarily exclusive. 
“Including” is not limiting.  The
terms and conditions hereof inure to the benefit of and are binding upon the
parties’ respective permitted successors and assigns.  This Note is subject to all the terms and
conditions of the Loan Agreement.

 

IN
WITNESS WHEREOF, Borrower has caused this Note to be executed by a duly
authorized officer as of the day and year first above written.

 

	
   

  	
  ARYx THERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  

 

 

Exhibit I

 

COLLATERAL

 

This
FINANCING STATEMENT and SECURITY AGREEMENT covers all of Debtor’s interests in
all of the following types or items of property, wherever located and whether
now owned or hereafter acquired, and Debtor hereby grants Secured Party a
security interest therein as collateral for the payment and performance of all
present and future indebtedness, liabilities, guarantees and obligations of
Debtor to Secured Party, howsoever arising. 
Debtor agrees that said security interest may be enforced by Secured
Party in accordance with the terms of all security and other agreements between
Secured Party and Debtor, the California Uniform Commercial Code, or both, and
that this document shall be fully effective as a security agreement, even if there
is no other security or other agreement between Secured Party or Debtor:

 

All
assets of the Debtor; all personal property of Debtor;

 

All
“accounts”, “general intangibles”, “chattel paper”, “contract rights”, “documents”,
“instruments”, “deposit accounts”, “inventory”, “farm products”, “fixtures” and
“equipment”, as such terms are defined in Division 9 of the California Uniform
Commercial Code in effect on the date hereof;

 

All
general intangibles of every kind, including without limitation intellectual property;

 

All
patents, patent applications, all extensions, reissues, substitutes,
continuations, continuations-in-part, divisionals, patents of addition,
re-examinations and renewals thereof, and patents issuing therefrom, and any
other proprietary rights related to any of the foregoing (including, without
limitation, remedies against infringements thereof and rights of protection of
an interest therein under the laws of all jurisdictions) and any and all
foreign counterparts of any of the foregoing;

 

All
copyrights, copyright applications;

 

All
trade names, and trademarks (and the goodwill of the business symbolized
thereby), trademark applications, all extensions, reissues, substitutes,
continuations, continuations-in-part, divisionals, and renewals thereof, and
any other proprietary rights related to any of the foregoing (including,
without limitation, remedies against infringements thereof and rights of
protection of an interest therein under the laws of all jurisdictions) and any
and all foreign counterparts of any of the foregoing;

 

All
federal, state and local tax refunds and claims of all kinds; all rights as a
licensor or licensee or any kind; all customer lists, trade secrets, telephone
numbers, processes, proprietary information, and purchase orders, and all
rights to purchase, lease sell, or otherwise acquire or deal with real or
personal property and all rights relating thereto;

 

All
returned and repossessed goods and all rights as a seller of goods; all
collateral securing any of the foregoing; all deposit accounts, special and
general, whether on deposit with Secured Party or others;

 

All
life and other insurance policies, claims in contract, tort or otherwise, and
all judgments now or hereafter arising therefrom;

 

All
right, title and interest of Debtor, and all of Debtor’s rights, remedies,
security and liens, in, to and in respect of all accounts and other collateral,
including, without limitation, rights of stoppage in transit, replevin,
repossession and reclamation and other rights and remedies of an unpaid vendor,
lienor or secured party, and all guarantees and other contracts of suretyship
with respect to any accounts and other collateral, and all deposits and other
security for any accounts and other collateral, and all credit and other insurance;

 

 

All
notes, drafts, letters of credit, contract rights, and things in action; all
drawings, specifications, blueprints and catalogs; and all raw materials, work
in process, materials used or consumed in Debtor’s business, goods, finished
goods, returned goods and all other goods and inventory of whatsoever kind or
nature, any and all wrapping, packaging, advertising and shipping materials,
and all documents relating thereto, and all labels and other devices, names and
marks affixed or to be affixed thereto for purposes of selling or identifying
the same or the seller or manufacturer thereof;

 

All
inventory, raw materials and work in progress wherever located; all present and
future claims against any supplier of any of the foregoing, including claims
for defective goods or overpayments to or undershipments by suppliers; all
proceeds arising from the lease or rental of any of the foregoing; INVENTORY
RETURNED BY DEBTOR TO ITS SUPPLIERS SHALL REMAIN SUBJECT TO SECURED PARTY’S
SECURITY INTEREST;

 

All
equipment and fixtures, NONE OF WHICH THE DEBTOR IS AUTHORIZED TO SELL, LEASE
OR OTHERWISE DISPOSE OF WITHOUT THE WRITTEN CONSENT OF SECURED PARTY, including
without limitation all machinery, machine tools, motors, controls, parts,
vehicles, workstations, tools, dies, jigs, furniture, furnishings and fixtures;
and all attachments, accessories, accessions and property now or hereafter
affixed to or used in connection with any of the foregoing, and all
substitutions and replacements for any of the foregoing; all warranty and other
claims against any vendor or lessor of any of the foregoing;

 

All
investment property;

 

All
books, records, ledger cards, computer data and programs and other property and
general intangibles at any time evidencing or relating to any or all of the
foregoing; and

 

Any
and all proceeds, products, replacements, additions, accessions and
substitutions of or with respect to any of the foregoing, including  all cash and non-cash products and proceeds of any of the
foregoing, in whatever form, including proceeds in the form of inventory,
equipment or any other form of personal property, including proceeds of
proceeds and proceeds of insurance, and all claims by Debtor against third
parties for loss or damage to, or destruction of, or otherwise relating to, any
or all of the foregoing.

 

	
  “DEBTOR”

  	
   

  	
  “SECURED PARTY”

  
	
   

  	
   

  	
   

  
	
  ARYx
  THERAPEUTICS, INC.

  	
   

  	
  LIGHTHOUSE
  CAPITAL PARTNERS V, L.P.

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
  LIGHTHOUSE
  MANAGEMENT PARTNERS V, L.L.C., its general partner

  
	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  

 

 

Exhibit I-A

 

COLLATERAL

 

This
FINANCING STATEMENT and SECURITY AGREEMENT covers all of Debtor’s interests in
all of the following types or items of property, wherever located and whether
now owned or hereafter acquired, and Debtor hereby grants Secured Party a
security interest therein as collateral for the payment and performance of all
present and future indebtedness, liabilities, guarantees and obligations of
Debtor to Secured Party, howsoever arising. 
Debtor agrees that said security interest may be enforced by Secured
Party in accordance with the terms of all security and other agreements between
Secured Party and Debtor, the California Uniform Commercial Code, or both, and
that this document shall be fully effective as a security agreement, even if
there is no other security or other agreement between Secured Party or Debtor:

 

All
assets of the Debtor; all personal property of Debtor;

 

All
“accounts”, “general intangibles”, “chattel paper”, “contract rights”, “documents”,
“instruments”, “deposit accounts”, “inventory”, “farm products”, “fixtures” and
“equipment”, as such terms are defined in Division 9 of the California Uniform
Commercial Code in effect on the date hereof;

 

All
general intangibles of every kind

 

All
federal, state and local tax refunds and claims of all kinds; all rights as a
licensor or licensee or any kind; all customer lists, trade secrets, telephone
numbers, processes, proprietary information, and purchase orders, and all
rights to purchase, lease sell, or otherwise acquire or deal with real or
personal property and all rights relating thereto;

 

All
returned and repossessed goods and all rights as a seller of goods; all
collateral securing any of the foregoing; all deposit accounts, special and
general, whether on deposit with Secured Party or others;

 

All
life and other insurance policies, claims in contract, tort or otherwise, and
all judgments now or hereafter arising therefrom;

 

All
right, title and interest of Debtor, and all of Debtor’s rights, remedies,
security and liens, in, to and in respect of all accounts and other collateral,
including, without limitation, rights of stoppage in transit, replevin,
repossession and reclamation and other rights and remedies of an unpaid vendor,
lienor or secured party, and all guarantees and other contracts of suretyship
with respect to any accounts and other collateral, and all deposits and other
security for any accounts and other collateral, and all credit and other
insurance;

 

All
notes, drafts, letters of credit, contract rights, and things in action; all
drawings, specifications, blueprints and catalogs; and all raw materials, work
in process, materials used or consumed in Debtor’s business, goods, finished
goods, returned goods and all other goods and inventory of whatsoever kind or
nature, any and all wrapping, packaging, advertising and shipping materials,
and all documents relating thereto, and all labels and other devices, names and
marks affixed or to be affixed thereto for purposes of selling or identifying
the same or the seller or manufacturer thereof;

 

All
inventory, raw materials and work in progress wherever located; all present and
future claims against any supplier of any of the foregoing, including claims
for defective goods or overpayments to or undershipments by suppliers; all
proceeds arising from the lease or rental of any of the foregoing; INVENTORY
RETURNED BY DEBTOR TO ITS SUPPLIERS SHALL REMAIN SUBJECT TO SECURED PARTY’S
SECURITY INTEREST;

 

 

All
equipment and fixtures, NONE OF WHICH THE DEBTOR IS AUTHORIZED TO SELL, LEASE
OR OTHERWISE DISPOSE OF WITHOUT THE WRITTEN CONSENT OF SECURED PARTY, including
without limitation all machinery, machine tools, motors, controls, parts,
vehicles, workstations, tools, dies, jigs, furniture, furnishings and fixtures;
and all attachments, accessories, accessions and property now or hereafter
affixed to or used in connection with any of the foregoing, and all
substitutions and replacements for any of the foregoing; all warranty and other
claims against any vendor or lessor of any of the foregoing;

 

All
investment property;

 

All
books, records, ledger cards, computer data and programs and other property and
general intangibles at any time evidencing or relating to any or all of the
foregoing; and

 

Any
and all proceeds, products, replacements, additions, accessions and
substitutions of or with respect to any of the foregoing, including  all cash and non-cash products and proceeds of any of the
foregoing, in whatever form, including proceeds in the form of inventory,
equipment or any other form of personal property, including proceeds of
proceeds and proceeds of insurance, and all claims by Debtor against third
parties for loss or damage to, or destruction of, or otherwise relating to, any
or all of the foregoing.

 

Notwithstanding
the foregoing, Collateral shall not include any of the following:  (a) intellectual property, (b)All
patents, patent applications, all extensions, reissues, substitutes,
continuations, continuations-in-part, divisionals, patents of addition,
re-examinations and renewals thereof, and patents issuing therefrom, and any
other proprietary rights related to any of the foregoing (including, without
limitation, remedies against infringements thereof and rights of protection of
an interest therein under the laws of all jurisdictions) and any and all
foreign counterparts of any of the foregoing; (c) All copyrights,
copyright applications;and (d) all trade names, and trademarks (and the
goodwill of the business symbolized thereby), trademark applications, all
extensions, reissues, substitutes, continuations, continuations-in-part,
divisionals, and renewals thereof, and any other proprietary rights related to
any of the foregoing (including, without limitation, remedies against
infringements thereof and rights of protection of an interest therein under the
laws of all jurisdictions) and any and all foreign counterparts of any of the
foregoing;

 

	
  “DEBTOR”

  	
   

  	
  “SECURED PARTY”

  
	
   

  	
   

  	
   

  
	
  ARYx
  THERAPEUTICS, INC.

  	
   

  	
  LIGHTHOUSE
  CAPITAL PARTNERS V, L.P.

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
  LIGHTHOUSE
  MANAGEMENT PARTNERS V, L.L.C., its general partner

  
	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  

 

 

Exhibit II

 

Intellectual Property Security
Agreement

 

 

Exhibit III

 

Intercreditor AgreementEXHIBIT
10.6

 

INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

This
Intellectual Property Security Agreement (“Security Agreement”) is made
as of August 13, 2010, by and between ARYx Therapeutics, Inc.,
a Delaware corporation (“Debtor”), and Lighthouse
Capital Partners V, L.P. (“Lender”).

 

RECITALS

 

A.                                   Debtor is
indebted to Lender for loans advanced and other financial accommodations
provided pursuant to a Loan and Security Agreement No. 4521 originally
dated March 28, 2005.

 

B.                                     Debtor has
granted a security interest in certain intangible property to Lender for
purposes of securing the obligations of Debtor to Lender.

 

C.                                     In
consideration of new value and other financial accommodations provided by
Lender and on account of other amounts due Lender, Debtor has agreed to grant
Lender the security interests in Debtor’s intellectual property on the terms
set forth herein.

 

NOW,
THEREFORE, the parties hereto agree as follows:

 

1.                                      Definitions.  The following capitalized terms shall mean
the following in this Agreement.

 

1.1                               “Amendment No. 8” means Amendment No. 8
to Loan and Security Agreement dated as of August 13, 2010.

 

1.2                               “Bridge Lender” has the meaning
ascribed to the term in Amendment No. 8.

 

1.3                               “Bridge Security Interest” has the
meaning ascribed to the term in Amendment No. 8.

 

1.4                               “Eligible Bridge Debt” has the meaning
ascribed to the term in Amendment No. 8.

 

1.5                               “Intercreditor Agreement” has the
meaning ascribed to the term in Amendment No. 8.

 

1.6                               “IP collateral” means all of the
following now or hereafter existing, created or acquired or held by Debtor:

 

(a)                                  Any and all copyright rights, copyright applications, copyright
registrations and like protections in each work of authorship and derivative
work thereof, whether published or unpublished and whether or not the same also
constitutes a trade secret, including, without limitation, those set forth on Exhibit A
attached hereto and incorporated herein by this reference (collectively, the “Copyrights”);

 

(b)                                 Any and all trade secrets, any and all intellectual property rights in
computer software and computer software products, and any other proprietary
rights to any process, method or technology of any kind or nature;

 

(c)                                  Any and all design rights which may be available to Debtor;

 

(d)                                 All patents, patent applications and like protections including, without
limitation, those set forth on Exhibit B attached hereto and
incorporated herein by this reference together 

 

 

with all improvements, extensions, reissues,
substitutes, continuations, continuations-in-part, divisionals, patents of
addition, re-examinations and renewals thereof, and patents issuing therefrom,
and any other proprietary rights related to any of the foregoing (including,
without limitation, remedies against infringements thereof and rights of protection
of an interest therein under the laws of all jurisdictions) and any and all
foreign counterparts of any of the foregoing (collectively, the “Patents”);

 

(e)                                  All trademark and service mark rights, whether registered or not,
applications to register and registrations of the same and like protections,
and the entire goodwill of the business of Debtor connected with and symbolized
by such trademarks, including, without limitation, those set forth on Exhibit C
attached hereto and incorporated herein by this reference together with all
extensions, reissues, substitutes, continuations, and renewals thereof, and any
other proprietary rights related to any of the foregoing (including, without
limitation, remedies against infringements thereof and rights of protection of
an interest therein under the laws of all jurisdictions) and any and all
foreign counterparts of any of the foregoing;
(collectively, the “Trademarks”);

 

(f)                                    Any and all claims for damages by way of past, present and future
infringement of any of the rights included above, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of
the intellectual property rights identified above;

 

(g)                                 All licenses or other rights to use any of the Copyrights, Patents or
Trademarks, and all license fees and royalties arising from such use to the
extent permitted by such license or rights;

 

(h)                                 All amendments, renewals and extensions of any of the Copyrights, Patents
or Trademarks; and

 

(i)                                     Any and all proceeds, products, replacements, additions, accessions and
substitutions of or with respect to any of the foregoing, including, without
limitation, all payments under insurance or any indemnity or warranty payable
in respect of any of the foregoing.

 

1.7                               “Loan Agreement” means the Loan and
Security Agreement No. 4521 originally dated March 28, 2005, as
amended in writing from time to time, including Amendment No. 8.

 

1.8                               “Loan Documents” has the meaning
ascribed to the term in the Loan Agreement.

 

1.9                               “New Value Obligations” has the meaning
ascribed to the term in Amendment No. 8.

 

1.10                        “Obligations” has the meaning ascribed
to the term in the Loan Agreement.

 

1.11                        “Permitted Lien” has the meaning
ascribed to the term in the Loan Agreement.

 

2.                                      Grant of First Senior Security Interest.  As collateral security for the
prompt and complete payment and performance of the New Value Obligations,
Debtor hereby transfers, conveys and grants a security interest in and
mortgages to Lender, as security, in and to Debtor’s entire right, title and
interest in, to and under the IP Collateral.

 

3.                                      Grant of Junior Security Interest.  As collateral security for the prompt and
complete payment and performance of all of Debtor’s present or future
indebtedness, obligations and liabilities to Lender, including without
limitation, the Obligations, Debtor hereby transfers, conveys and grants a
security interest in and mortgages to Lender, as security, the IP Collateral.

 

 

4.                                      Priority of Financing Statements.  Lender will file in the appropriate filing
office, separate but identical financing statements with respect to the
security interests granted pursuant to Section and Section 3
hereof, respectively.  The financing
statement filed first in time shall for all purposes perfect the security
interest granted pursuant to Section 2 hereof.

 

5.                                      Authorization and Request.  Debtor authorizes and requests that the
Registrar of Copyrights and the Commissioner of Patents and Trademarks record
this Security Agreement.

 

6.                                      Covenants and Warranties.  Debtor represents, warrants, covenants and
agrees as follows:

 

6.1                               Debtor is now the sole owner of the IP
Collateral, except for the non-exclusive licenses granted by Debtor to its
customers in the ordinary and normal course of business as now conducted;

 

6.2                               Performance of this Security Agreement does
not conflict with or result in a breach of any agreement to which Debtor is a
party or by which Debtor is bound, except to the extent that certain
intellectual property agreements prohibit the assignment of the rights thereunder
to a third party without the licensor’s or other party’s consent and this
Security Agreement constitutes an assignment;

 

6.3                               During the term of this Security Agreement,
Debtor shall not without Lender’s prior written authorization sell, transfer,
assign or otherwise encumber any interest in the IP Collateral, except for
(i) non-exclusive licenses granted by Debtor in the ordinary and normal
course of its business as now conducted or as set forth in this Security
Agreement; (ii) the Bridge Security Interest; and (iii) subject to
Debtor’s execution of appropriate documents, in form acceptable to Lender, to
perfect or continue the perfection of Lender’s interest in the IP Collateral,
transfers to affiliates of Debtor;

 

6.4                               To its knowledge, each of the Patents is valid
and enforceable, and no part of the IP Collateral has been judged invalid or
unenforceable, in whole or in part, and no claim has been made that any part of
the IP Collateral violates the rights of any third party;

 

6.5                               Debtor shall advise Lender of any material
changes in the composition of the IP Collateral by identifying such material
changes in the Quarterly Report (as hereinafter defined), including but not
limited to any subsequent ownership right of Debtor in or to any Copyright, Patent
or Trademark not specified in this Security Agreement;

 

6.6                               Debtor shall (i) protect, defend and
maintain the validity and enforceability of the Copyrights, Patents and
Trademarks, (ii) use its best efforts to detect infringements of the
Copyrights, Patents and Trademarks and promptly advise Lender in writing of
material infringements detected and (iii) not allow any Copyrights,
Patents or Trademarks to be abandoned, forfeited or dedicated to the public
without the written consent of Lender, which shall not be unreasonably
withheld, unless Debtor determines that reasonable business practices suggest
that abandonment is appropriate;

 

6.7                               Debtor shall promptly register the most recent
version of Debtor’s material Copyrights, Patents and Trademarks if not so
already registered, as Lender may reasonably request from time to time based on
its review of the Quarterly Report (as hereinafter defined) and shall, from
time to time, execute and file such other instruments, and take such further
actions as Lender may reasonably request from time to time to perfect or
continue the perfection of Lender’s interest in the IP Collateral;

 

6.8                               This Security Agreement creates, and in the
case of after acquired IP Collateral, this Security Agreement will create at
the time Debtor first has rights in such after acquired IP Collateral, in favor
of Lender valid and perfected first priority security interests in the IP
Collateral in the United 

 

 

States securing the payment and performance
of all present or future indebtedness, obligations and liabilities of Debtor to
Lender, including, without limitation, such indebtedness, obligations and
liabilities under the Loan Agreement and the other Loan Documents, upon making
the filings referred to in Section 4 hereof, subject only to
Permitted Liens;

 

6.9                               To its knowledge, except for, and upon, the
filings with, as applicable, (1) the United States Patent and Trademark
office with respect to the Patents and Trademarks, (2) the Register of
Copyrights with respect to the Copyrights and (3) the UCC Division of the
Secretary of State of Delaware, necessary to perfect the security interests
created hereunder, and except as has been already made or obtained, no
authorization, approval or other action by, and no notice to or filing with,
any United States governmental authority or United States regulatory body is
required either (a) for the grant by Debtor of the security interests
granted hereby or for the execution, delivery or performance of this Security
Agreement by Debtor in the United States or (b) for the perfection in the
United States or the exercise by Lender of its rights and remedies hereunder;

 

6.10                        All information heretofore, herein or
hereafter supplied to Lender by or on behalf of Debtor with respect to the IP
Collateral is accurate and complete in all material respects;

 

6.11                        Debtor shall not enter into any agreement that
would materially impair or conflict with Debtor’s obligations hereunder without
Lender’s prior written authorization, which authorization shall not be unreasonably
withheld.  Debtor shall not permit the
inclusion in any material contract to which it becomes a party of any
provisions that could or might in any way prevent the creation of a security
interest in Debtor’s rights and interests in any property included within the
definition of the IP Collateral acquired under such contracts; and

 

6.12                        Upon any executive officer of Debtor obtaining
actual knowledge thereof, Debtor will promptly notify Lender in writing of any
event that materially adversely affects the value of any IP Collateral, the
ability of Debtor to dispose of any IP Collateral or the rights and remedies of
Lender in relation thereto, including the levy of any legal process against any
of the IP Collateral.

 

6.13                        Within ten (10) days of the date hereof,
Debtor shall, with respect to all U.S. Patents (and Patent applications) listed
on Exhibit B cause to be filed and recorded recordation notices at
the United States Patent and Trademark Office of the assignments evidencing the
ownership of such Patents and patent applications in the sole name of the
Debtor.

 

7.                                      Lender’s Rights.  Lender shall have the right, but not the
obligation, to take, at Debtor’s sole expense, any actions that Debtor is
required under this Security Agreement to take but which Debtor fails to take,
after fifteen (15) days’ notice to Debtor. 
Debtor shall reimburse and indemnify Lender for all reasonable costs and
reasonable expenses incurred in the reasonable exercise of its rights under
this Section 7.

 

8.                                      Inspection Rights.  Debtor hereby grants to Lender and its
employees, representatives and agent’s the right to visit once per calendar
year (unless an Event of Default has occurred and is continuing), during
reasonable hours upon prior reasonable written notice to Debtor, any of Debtor’s
plants and facilities that manufacture, install or store products (or that have
done so during the prior six-month period) that are sold utilizing any of the
IP Collateral, and to inspect the products and quality control records relating
thereto upon reasonable written notice to Debtor and as often as may be
reasonably requested.

 

 

9.                                      Further Assurances; Attorney In Fact.

 

9.1                               On a quarterly basis, Debtor agrees to deliver
to Lender a report, in form acceptable to Lender and certified by an officer of
Debtor, which lists all Copyrights, Patents and Trademarks that are material to
the operation of Debtor’s business on an on-going basis, and in which Lender
does not already have perfected security interests (the “Quarterly Report”);
provided, however, Debtor may provide a general description of
the Copyrights by type.

 

9.2                               On a continuing basis, Debtor will make,
execute, acknowledge and deliver, and file and record in the proper filing and
recording places in the United States, all such instruments, including
appropriate financing and continuation statements and collateral agreements and
filings with the United States Patent and Trademark Office and the Register of
Copyrights, and take all such action as may reasonably be necessary or
advisable, or as reasonably requested by Lender, to perfect Lender’s security
interest in all Copyrights, Patents and Trademarks, which Lender reasonably
identifies pursuant to Section above as material to the operation of
Debtor’s business on an on-going basis or the value of the IP Collateral, and
otherwise to carry out the intent and purposes of this Security Agreement, or
for assuring and confirming to Lender the grant or perfection of a security
interests in all IP Collateral.

 

9.3                               Debtor hereby irrevocably appoints Lender as
Debtor’s attorney-in-fact, with full authority in the place and stead of Debtor
and in the name of Debtor, from time to time in Lender’s discretion, to take
any of the following actions and to execute any of the following instruments
(i) modify, in its reasonable discretion, this Security Agreement without
first obtaining Debtor’s approval of or signature to such modification by
amending Exhibit A, Exhibit B or Exhibit C
hereof, as appropriate, to include reference to any material right, title or
interest in any Copyrights, Patents or Trademarks acquired by Debtor after the
execution hereof or to delete any reference to any right, title or interest in
any Copyrights, Patents or Trademarks in which Debtor no longer has or claims
any right, title or interest, (ii) file, in its reasonable discretion, one
or more financing or continuation statements and amendments thereto, relative
to any of the IP Collateral without the signature of Debtor where permitted by
law and (iii) after the occurrence and during the continuance of an Event
of Default, to transfer the IP Collateral into the name of Lender or a third
party to the extent permitted under the California Uniform Commercial Code.

 

10.                               Events of Default.  The occurrence of any of the following shall
constitute an “Event of Default” under this Security Agreement:

 

10.1                        An Event of Default occurs under the Loan
Agreement or any of the other Loan Documents;

 

10.2                        Debtor breaches any warranty or agreement in
any material respect made by Debtor in this Security Agreement and, as to any
breach that is capable of cure, Debtor fails to cure such breach within thirty
(30) days of the occurrence of such breach;

 

10.3                        Debtor shall fail to comply with the covenant
set forth in Section 6 hereof; and

 

10.4                        Bridge Lender seeks to make demand for payment
of any portion of the Eligible Bridge Debt, gives notice of a default with
respect to the Eligible Bridge Debt, or threatens or seeks to undertake any
action to enforce its rights with respect to the Bridge Security Interest.

 

11.                               Remedies.  Upon the occurrence and during the
continuance of an Event of Default, Lender shall have the right to exercise all
the remedies of a secured party under the California Uniform Commercial Code,
including, without limitation, the right to require Debtor to assemble the IP
Collateral and any tangible property in which Lender has security interests and
to make it available to Lender at a place designated by Lender.  Lender shall have a nonexclusive, royalty
free license to use the Copyrights, Patents and Trademarks to the extent
reasonably necessary to permit Lender to exercise its rights and 

 

 

remedies upon the occurrence and during the
continuance of an Event of Default. 
Debtor will pay any expenses (including reasonable attorneys’ fees)
incurred by Lender in connection with the exercise of any of Lender’s rights
hereunder, including, without limitation, any expense incurred in disposing of
the IP Collateral.  All of Lender’s
rights and remedies with respect to the IP Collateral shall be cumulative.

 

12.                               Indemnity.  Debtor agrees to defend, indemnify and hold
harmless Lender and its officers, employees, and agents against: (a) all
obligations, demands, claims, and liabilities claimed or asserted by any other
party in connection with the transactions contemplated by this Security
Agreement and (b) all losses or expenses in any way suffered, incurred, or
paid by any of them as a result of or in any way arising out of, following or
consequential to transactions between Lender and Debtor, whether under this
Security Agreement or otherwise (including, without limitation, reasonable
attorneys’ fees and reasonable expenses), except for claims and losses
described in clauses (a) and (b), arising from or out of the gross
negligence or willful misconduct of Lender.

 

13.                               Termination.  At such time as Debtor shall completely
satisfy all of the obligations secured hereunder or otherwise pursuant to the
terms of the Loan Documents, Lender shall execute and deliver to Debtor all
deeds, assignments and other instruments as may be necessary or proper to
terminate the security interests granted hereunder, subject to any disposition
thereof which may have been made by Lender pursuant hereto.

 

14.                               No Failure or Delay.  No failure or delay on the part of Lender, in
the exercise of any power, right or privilege hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise thereof.

 

15.                               Attorneys’ Fees. Debtor shall pay
Lender on demand all reasonable attorneys and/or legal fees and all other costs
and expenses incurred by Lender in enforcing Lenders’s rights under this
Security Agreement, including without limitation all costs of preserving or
disposing of the IP Collateral.

 

16.                               Amendments.  Except as otherwise provided in Section ,
this Security Agreement may be amended only by a written instrument signed by
Lender.

 

17.                               Counterparts.  This Security Agreement may be executed in
any number of counterparts, each of which when so delivered shall be deemed an
original, but all such counterparts shall constitute but one and the same
instrument.  Each such Security Agreement
shall become effective upon the execution of a counterpart hereof or thereof by
each of the parties hereto and telephonic notification that such executed
counterparts has been received by Debtor and Lender.

 

18.                               Governing Law; Jurisdiction; Jury Waiver.  This Security Agreement shall be
governed by, and construed in accordance with, the internal laws of the State
of California, without regard to principles of conflicts of law.  Debtor and Lender consent to the exclusive
jurisdiction of any state or federal court located in San Francisco County,
California.  DEBTOR AND LENDER EACH WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF
ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SECURITY
AGREEMENT AND ANY OTHER LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED
HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND
ALL OTHER COMMON LAW OR STATUTORY CLAIMS.

 

 

19.                               Conflict.  In the event of a conflict between any term
and/or provision contained in this Security Agreement with any term and/or
provision contained in any of the Loan Documents, the term and/or provision of
the Loan Agreement shall govern.

 

REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

 

 

IN
WITNESS WHEREOF, the parties hereto have executed this Security Agreement on
the day and year first above written.

 

	
  “Debtor”

  	
   

  	
  “Lender”

  
	
   

  	
   

  	
   

  
	
  ARYx
  THERAEUTICS, INC.

  	
   

  	
  LIGHTHOUSE
  CAPITAL PARTNERS V, L.P.

  
	
   

  	
   

  	
  By:
  Lighthouse Management Partners V, L.L.C.,

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Paul Goddard, Ph.D.

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  	
  its
  general partner

  
	
  Name:

  	
  Paul Goddard, Ph.D.

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Chairman and Chief Executive Officer

  	
   

  	
  By:
  

  	
  /s/
  Thomas Conneely

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name:
  

  	
  Thomas
  Conneely

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Title:
  

  	
  Vice
  President

  

 

SIGNATURE PAGE TO ARYx
THERAPEUTICS, INC.

INTELLECTUAL PROPERTY
SECURITY AGREEMENT

 

 

Exhibit A

 

COPYRIGHTS

 

1.                                       REGISTERED:
List titles below or indicate “None”

 

None.

 

2.                                       UNREGISTERED:
List titles below or indicate “None”

 

None.

 

3.                                       APPLICATIONS IN
PROCESS: List titles, applicable dates, application numbers, etc. below or
indicate “None”

 

None.

 

 

Exhibit B

 

PATENTS

 

	
  Title

  	
   

  	
  Materials
  and Methods for the Treatment of Depression

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1009

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2001255654

  	
   

  	
  24-Apr-2001

  	
   

  	
  2001255654

  	
   

  	
  6-Jan-2006

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2405025

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1928840.6

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001-577944

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Expired

  	
   

  	
  60/199343

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1009

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841749

  	
   

  	
  24-Apr-2001

  	
   

  	
  6469064

  	
   

  	
  22-Oct-2002

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/273702

  	
   

  	
  18-Oct-2002

  	
   

  	
  6809116

  	
   

  	
  26-Oct-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/931586

  	
   

  	
  31-Aug-2004

  	
   

  	
  7256191

  	
   

  	
  14-Aug-2007

  	
   

  	
  22-Dec-2023

  
	
  04-1009

  	
   

  	
  D

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/13275

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  I

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  US05/29868

  	
   

  	
  23-Aug-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel compounds for treatment of cardiac arrhythmia, synthesis, and methods of use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1010

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002360582

  	
   

  	
  10-Dec-2002

  	
   

  	
  2002360582

  	
   

  	
  24-Sep-2009

  	
   

  	
  10-Dec-2022

  
	
  04-1010

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2469730

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2795850.3

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-551127

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/339898

  	
   

  	
  10-Dec-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-Dec-2002

  
	
  04-1010

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/319073

  	
   

  	
  10-Dec-2002

  	
   

  	
  6710070

  	
   

  	
  23-Mar-2004

  	
   

  	
  10-Dec-2022

  
	
  04-1010

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/799546

  	
   

  	
  11-Mar-2004

  	
   

  	
  6869972

  	
   

  	
  22-Mar-2005

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  B1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/074152

  	
   

  	
  7-Mar-2005

  	
   

  	
  7037933

  	
   

  	
  2-May-2006

  	
   

  	
  11-Mar-2024

  
	
  04-1010

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US02/39849

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Ultrashort Acting Hypnotic Barbiturates

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1011

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2001257230

  	
   

  	
  24-Apr-2001

  	
   

  	
  2001257230

  	
   

  	
  5-Jan-2007

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2404898

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-1011

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1930722.2

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2001-578413

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/199144

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1011

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841738

  	
   

  	
  24-Apr-2001

  	
   

  	
  6387914

  	
   

  	
  14-May-2002

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  A-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  10/145601

  	
   

  	
  13-May-2002

  	
   

  	
  6683086

  	
   

  	
  27-Jan-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/763904

  	
   

  	
  23-Jan-2004

  	
   

  	
  7041673

  	
   

  	
  9-May-2006

  	
   

  	
  21-Jul-2022

  
	
  04-1011

  	
   

  	
  C-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Granted

  	
   

  	
  12/009446

  	
   

  	
  20-Dec-2007

  	
   

  	
  RE41289E

  	
   

  	
  27-Apr-2010

  	
   

  	
  23-Jan-2024

  
	
  04-1011

  	
   

  	
  D

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US01/13246

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Non-Oxidatively Metabolized Compounds and Compositions, Synthetic Pathways Therefore, and Uses Thereof

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1015

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002331749

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2457532

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2768732.6

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-522469

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/314792

  	
   

  	
  24-Aug-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Aug-2002

  
	
  04-1015

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/228670

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  A1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  11/330881

  	
   

  	
  12-Jan-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/27298

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Benzofuranyl Derivatives Useful For The Treatment Of Cardiac Arrhythmia

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1026

  	
   

  	
  B1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005232701

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0509740-1

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2560336

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  200580012140.X

  	
   

  	
  8-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  5735166

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B4-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Abandoned

  	
   

  	
  7111251.4

  	
   

  	
  18-Oct-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B7

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  178127

  	
   

  	
  14-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B6

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2686/KOLNP/2007

  	
   

  	
  15-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B8

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-507557

  	
   

  	
  6-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B14

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7022953

  	
   

  	
  1-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B9

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/011647

  	
   

  	
  6-Oct-2006

  	
   

  	
  261929

  	
   

  	
  5-Nov-2008

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  B10

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20065156

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B11

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501990

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-1026

  	
   

  	
  B12

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006139649

  	
   

  	
  8-Nov-2006

  	
   

  	
  2373199

  	
   

  	
  20-Nov-2009

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/560917

  	
   

  	
  9-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9-Apr-2005

  
	
  04-1026

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/101995

  	
   

  	
  8-Apr-2005

  	
   

  	
  7105568

  	
   

  	
  12-Sep-2006

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/423559

  	
   

  	
  12-Jun-2006

  	
   

  	
  7351842

  	
   

  	
  1-Apr-2008

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  C-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  11/936620

  	
   

  	
  7-Nov-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/12138

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B13

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/07666

  	
   

  	
  8-Apr-2005

  	
   

  	
  2006/07666

  	
   

  	
  26-Mar-2008

  	
   

  	
  8-Apr-2025

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Analgesic Delivery Systems and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1027

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002361709

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2469200

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2797347.8

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-552296

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/341743

  	
   

  	
  17-Dec-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17-Dec-2002

  
	
  04-1027

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  RCE

  	
   

  	
  Transfered

  	
   

  	
  10/321410

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/40183

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Hypertension and Angina

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1028

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002337842

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2462913

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2773743.6

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-534399

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/328588

  	
   

  	
  10-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-Oct-2002

  
	
  04-1028

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/269139

  	
   

  	
  10-Oct-2002

  	
   

  	
  6608097

  	
   

  	
  19-Aug-2003

  	
   

  	
  10-Oct-2022

  
	
  04-1028

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/643699

  	
   

  	
  18-Aug-2003

  	
   

  	
  7265142

  	
   

  	
  4-Sep-2007

  	
   

  	
  10-Oct-2022

  
	
  04-1028

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/32562

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Hypercholesterolemia

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1029

  	
   

  	
  B3

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003259188

  	
   

  	
  18-Jan-2005

  	
   

  	
   

  	
   

  	
  19-Jun-2008

  	
   

  	
  21-Jul-2023

  

 

 

	
  04-1029

  	
   

  	
  B3-DIV

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  2008202241

  	
   

  	
  21-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2492906

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B1

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  3765847.3

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B4

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2004523222

  	
   

  	
  18-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/397076

  	
   

  	
  19-Jul-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Jul-2003

  
	
  04-1029

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/624659

  	
   

  	
  21-Jul-2003

  	
   

  	
  6951877

  	
   

  	
  4-Oct-2005

  	
   

  	
  21-Jul-2023

  
	
  04-1029

  	
   

  	
  A1

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  11/220364

  	
   

  	
  6-Sep-2005

  	
   

  	
  7384973

  	
   

  	
  10-Jun-2008

  	
   

  	
  21-Jul-2023

  
	
  04-1029

  	
   

  	
  A1-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  12/027552

  	
   

  	
  7-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US03/022756

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel anticholinergic compounds for the treatment of incontinence

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1030

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002307118

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2443346

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2774092.7

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-500035

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281134

  	
   

  	
  3-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3-Apr-2002

  
	
  04-1030

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/350516

  	
   

  	
  18-Jan-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jan-2003

  
	
  04-1030

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/116202

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/10614

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  5-HT3 Receptor Antagonists and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1031

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2003210610

  	
   

  	
  21-Jan-2003

  	
   

  	
  2003210610

  	
   

  	
  13-Mar-2008

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2473392

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
  F1

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F2

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F3

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F4

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F5

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-561601

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/350504

  	
   

  	
  18-Jan-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jan-2003

  
	
  04-1031

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/348669

  	
   

  	
  21-Jan-2003

  	
   

  	
  6770655

  	
   

  	
  3-Aug-2004

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Abandoned

  	
   

  	
  10/857108

  	
   

  	
  28-May-2004

  	
   

  	
  7125886

  	
   

  	
  24-Oct-2006

  	
   

  	
  25-Jun-2023

  

 

 

	
  04-1031

  	
   

  	
  B-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
  B1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/551562

  	
   

  	
  20-Oct-2006

  	
   

  	
  7501436

  	
   

  	
  10-Mar-2009

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US03/01876

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Compound for Treatment of Cardiac Arrhythmia, Synthesis and Method of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1032

  	
   

  	
  F

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  71102/94

  	
   

  	
  16-Jun-1994

  	
   

  	
  697687

  	
   

  	
  28-Jan-1999

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  K

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002211479

  	
   

  	
  4-Oct-2001

  	
   

  	
  2002211479

  	
   

  	
  13-Dec-2007

  	
   

  	
  4-Oct-2021

  
	
  04-1032

  	
   

  	
  G

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2164633

  	
   

  	
  16-Jun-1994

  	
   

  	
  2164633

  	
   

  	
  28-Nov-2006

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  G1

  	
   

  	
  CA

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  2566543

  	
   

  	
  16-Jun-1994

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  L

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2425245

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H2

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  69407785.2

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  H

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  M

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1979531.9

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H1

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  H3

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  N

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  480CHENP/2003

  	
   

  	
  4-Apr-2003

  	
   

  	
  209636

  	
   

  	
  5-Sep-2007

  	
   

  	
  4-Oct-2021

  
	
  04-1032

  	
   

  	
  H4

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  I

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  7-502201

  	
   

  	
  16-Jun-1994

  	
   

  	
  3435411

  	
   

  	
  6-Jun-2003

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  O

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002-541092

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H5

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  08/078371

  	
   

  	
  16-Jun-1993

  	
   

  	
  5364880

  	
   

  	
  15-Nov-1994

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  08/260869

  	
   

  	
  16-Jun-1994

  	
   

  	
  5440054

  	
   

  	
  8-Aug-1995

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  08/468602

  	
   

  	
  6-Jun-1995

  	
   

  	
  5849788

  	
   

  	
  15-Dec-1998

  	
   

  	
  15-Dec-2015

  
	
  04-1032

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  09/211246

  	
   

  	
  14-Dec-1998

  	
   

  	
  6130240

  	
   

  	
  10-Oct-2000

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  09/680880

  	
   

  	
  6-Oct-2000

  	
   

  	
  6316487

  	
   

  	
  13-Nov-2001

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  E

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US94/06812

  	
   

  	
  16-Jun-1994

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  J

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/31305

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Diabetes

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1036

  	
   

  	
  G1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001259130

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002327683

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2402123

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2460150

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1932617.2

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-1036

  	
   

  	
  H3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2763686.9

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H4

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  00845DELNP04

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G4

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001-578420

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H5

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-528791

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H6

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2004-7004172

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H7

  	
   

  	
  NZ

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  532261

  	
   

  	
  20-Sep-2002

  	
   

  	
  532261

  	
   

  	
  8-Jun-2006

  	
   

  	
  20-Sep-2022

  
	
  04-1036

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/199146

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1036

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281982

  	
   

  	
  6-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6-Apr-2002

  
	
  04-1036

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/297838

  	
   

  	
  13-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13-Jun-2002

  
	
  04-1036

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841351

  	
   

  	
  24-Apr-2001

  	
   

  	
  6680387

  	
   

  	
  20-Jan-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1036

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  09/961542

  	
   

  	
  21-Sep-2001

  	
   

  	
  6768008

  	
   

  	
  27-Jul-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1036

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/251522

  	
   

  	
  20-Sep-2002

  	
   

  	
  6958355

  	
   

  	
  25-Oct-2005

  	
   

  	
  25-Sep-2021

  
	
  04-1036

  	
   

  	
  E1

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  11/167925

  	
   

  	
  27-Jun-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  10/759617

  	
   

  	
  16-Jan-2004

  	
   

  	
  7022722

  	
   

  	
  4-Apr-2006

  	
   

  	
  20-Nov-2021

  
	
  04-1036

  	
   

  	
  G

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/13131

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/30017

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H8

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2004/1945

  	
   

  	
  20-Sep-2002

  	
   

  	
  2004/1945

  	
   

  	
  27-Jul-2005

  	
   

  	
  20-Sep-2022

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Isoxazolidine Compounds Useful in the Treatment of Diabetes, Hyperlipidemia, and Atherosclerosis in Mammals

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1038

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/234423

  	
   

  	
  21-Sep-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  21-Sep-2001

  
	
  04-1038

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/961538

  	
   

  	
  21-Sep-2001

  	
   

  	
  6784199

  	
   

  	
  31-Aug-2004

  	
   

  	
  29-Oct-2021

  
	
  04-1038

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  10/869516

  	
   

  	
  15-Jun-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1038

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/29853

  	
   

  	
  21-Sep-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Gastroesophageal Reflux Disease

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-882

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  20012575326

  	
   

  	
  7-Jun-2001

  	
   

  	
  2001275326

  	
   

  	
  19-May-2006

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  D1

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  2006201053

  	
   

  	
  19-May-2006

  	
   

  	
  2006201053

  	
   

  	
  19-May-2006

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2410939

  	
   

  	
  7-Jun-2001

  	
   

  	
  2410939

  	
   

  	
  16-Feb-2010

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1942028

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2002-501422

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/209926

  	
   

  	
  7-Jun-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jun-2001

  
	
  04-882

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/876698

  	
   

  	
  7-Jun-2001

  	
   

  	
  6552046

  	
   

  	
  22-Apr-2003

  	
   

  	
  7-Jun-2021

  

 

 

	
  04-882

  	
   

  	
  A-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Pending

  	
   

  	
  11/962592

  	
   

  	
  21-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  10/418842

  	
   

  	
  18-Apr-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/18365

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Coagulation Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-883

  	
   

  	
  B5-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005233614

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0508392-3

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2559568

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2.0058E+11

  	
   

  	
  8-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  DK/EP1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DIV

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  9175606.4

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  2340690

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DIVHK

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Pending

  	
   

  	
  10103549.8

  	
   

  	
  12-Apr-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B6

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Pending

  	
   

  	
  7110493.4

  	
   

  	
  27-Sep-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B8

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  178122

  	
   

  	
  14-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B8-DIV

  	
   

  	
  IL

  	
   

  	
  DIV

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B7

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2793/KOLNP/2006

  	
   

  	
  25-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B9

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-507551

  	
   

  	
  6-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B15

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7022954

  	
   

  	
  1-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B10

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/011637

  	
   

  	
  6-Oct-2006

  	
   

  	
  274321

  	
   

  	
  3-Mar-2010

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B11

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20065079

  	
   

  	
  3-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B12

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501866

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-883

  	
   

  	
  B5-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B13

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006139140

  	
   

  	
  7-Nov-2006

  	
   

  	
  2335501

  	
   

  	
  10-Oct-2008

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B13-DIV

  	
   

  	
  RU

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2008120295

  	
   

  	
  21-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/561121

  	
   

  	
  8-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  8-Apr-2005

  
	
  04-883

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/101714

  	
   

  	
  8-Apr-2005

  	
   

  	
  7253208

  	
   

  	
  7-Aug-2007

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/467813

  	
   

  	
  28-Aug-2006

  	
   

  	
  7285671

  	
   

  	
  23-Oct-2007

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/778482

  	
   

  	
  16-Jul-2007

  	
   

  	
  7666902

  	
   

  	
  23-Feb-2010

  	
   

  	
  28-Aug-2026

  
	
  04-883

  	
   

  	
  D-CON

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Published

  	
   

  	
  12/268109

  	
   

  	
  10-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/12091

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B14

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/07667

  	
   

  	
  8-Apr-2005

  	
   

  	
  2006/07667

  	
   

  	
  28-Nov-2007

  	
   

  	
  8-Apr-2025

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Coagulation Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-884

  	
   

  	
  G-AT

  	
   

  	
  AT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002256361

  	
   

  	
  24-Apr-2002

  	
   

  	
  2002256361

  	
   

  	
  15-May-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-BE

  	
   

  	
  BE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2445160

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  G-CH

  	
   

  	
  CH

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-CY

  	
   

  	
  CY

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-DE

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-DK

  	
   

  	
  DK

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-ES

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-FI

  	
   

  	
  FI

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-FR

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-GB

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-GR

  	
   

  	
  GR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-IE

  	
   

  	
  IE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-IT

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2002-583409

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  H-DIV

  	
   

  	
  JP

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2010-16130

  	
   

  	
  27-Jan-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  G-LU

  	
   

  	
  LU

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-MC

  	
   

  	
  MC

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-NL

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-PT

  	
   

  	
  PT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-SE

  	
   

  	
  SE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-TR

  	
   

  	
  TR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  

 

 

	
  04-884

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/199143

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-884

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/286079

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2002

  
	
  04-884

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/132750

  	
   

  	
  24-Apr-2002

  	
   

  	
  6864279

  	
   

  	
  8-Mar-2005

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  B-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/822129

  	
   

  	
  8-Apr-2004

  	
   

  	
  7145020

  	
   

  	
  5-Dec-2006

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  D1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Abandoned

  	
   

  	
  11/551302

  	
   

  	
  20-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  D1-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  12/125623

  	
   

  	
  22-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/13163

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Ultrashort-Acting Opioids for Transdermal Application

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-970

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002258714

  	
   

  	
  3-Apr-2002

  	
   

  	
  2002258714

  	
   

  	
  26-Jul-2007

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2443350

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2728672.3

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002-592864

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281080

  	
   

  	
  3-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3-Apr-2002

  
	
  04-970

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/116320

  	
   

  	
  3-Apr-2002

  	
   

  	
  6686377

  	
   

  	
  3-Feb-2004

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  G

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/771483

  	
   

  	
  2-Feb-2004

  	
   

  	
  7001915

  	
   

  	
  21-Feb-2006

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  H

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/257323

  	
   

  	
  24-Oct-2005

  	
   

  	
  7381735

  	
   

  	
  3-Jun-2008

  	
   

  	
  23-Sep-2024

  
	
  04-970

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/10620

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel Xanthines Having Adenosine A1-Receptor Antagonist Properties

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-971

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/397099

  	
   

  	
  19-Jul-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Jul-2003

  
	
  04-971

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/624713

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-971

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US03/22785

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Synthetic Methods and Intermediates for Steroisomeric Compounds useful for the Treatment of Gastrointestinal and Central Nervous System Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-972

  	
   

  	
  C5-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005205531

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C1-DIV1

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2008243243

  	
   

  	
  13-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-972

  	
   

  	
  J-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2006284601

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0506736-7

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0615691-6

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2551686

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2612893

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2620379

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0058E+11

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C4-DIV

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2.0101E+11

  	
   

  	
  8-Apr-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DIV

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  10153093.9

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Inactive

  	
   

  	
  6774511.7

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  6802848.9

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  9101838.5

  	
   

  	
  26-Feb-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C11

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  176569

  	
   

  	
  26-Jun-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  189202

  	
   

  	
  3-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C7

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1767/KOLNP/2006

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  928/KOLNP/2008

  	
   

  	
  3-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C6

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-549435

  	
   

  	
  6-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2008-520356

  	
   

  	
  4-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-529331

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C10

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7015208

  	
   

  	
  27-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-7007843

  	
   

  	
  31-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C8

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/007853

  	
   

  	
  7-Jul-2006

  	
   

  	
  261425

  	
   

  	
  16-Oct-2008

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C8-DIV

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2008/013107

  	
   

  	
  10-Oct-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-972

  	
   

  	
  H-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2007/016373

  	
   

  	
  18-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  Mx/a/2008/002666

  	
   

  	
  31-Aug-2006

  	
   

  	
  273587

  	
   

  	
  25-Jan-2010

  	
   

  	
  31-Aug-2026

  
	
  04-972

  	
   

  	
  J-MX-DIV

  	
   

  	
  MX

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  MX/a/2010/000896

  	
   

  	
  22-Jan-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C14

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20063568

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-NO

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20081562

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C12

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501306

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C12-DIV

  	
   

  	
  PH

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  1-2010-500400

  	
   

  	
  19-Feb-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2008-500353

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C9

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006128589

  	
   

  	
  4-Aug-2006

  	
   

  	
  2374244

  	
   

  	
  27-Nov-2009

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008112215

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-SG

  	
   

  	
  SG

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  200801146-2

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/534892

  	
   

  	
  7-Jan-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2005

  
	
  04-972

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/560938

  	
   

  	
  9-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2005

  
	
  04-972

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/031623

  	
   

  	
  7-Jan-2005

  	
   

  	
  7176218

  	
   

  	
  13-Feb-2007

  	
   

  	
  21-Aug-2025

  
	
  04-972

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  11/087167

  	
   

  	
  23-Mar-2005

  	
   

  	
  7282509

  	
   

  	
  16-Oct-2007

  	
   

  	
  27-May-2025

  
	
  04-972

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/696662

  	
   

  	
  5-Jul-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Jul-2006

  
	
  04-972

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/713149

  	
   

  	
  31-Aug-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  31-Aug-2006

  
	
  04-972

  	
   

  	
  F1

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/747762

  	
   

  	
  19-May-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-May-2007

  
	
  04-972

  	
   

  	
  G

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/805678

  	
   

  	
  23-Jun-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Jun-2007

  
	
  04-972

  	
   

  	
  H-US

  	
   

  	
  US

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  12/160655

  	
   

  	
  11-Jul-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  I

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/469264

  	
   

  	
  31-Aug-2006

  	
   

  	
  7326787

  	
   

  	
  5-Feb-2008

  	
   

  	
  31-Aug-2026

  
	
  04-972

  	
   

  	
  I-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  11/950914

  	
   

  	
  5-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  I-DIV2

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  12/109500

  	
   

  	
  25-Apr-2008

  	
   

  	
  7629466

  	
   

  	
  8-Dec-2009

  	
   

  	
  5-Dec-2027

  
	
  04-972

  	
   

  	
  K

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  11/765554

  	
   

  	
  20-Jun-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  M

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Published

  	
   

  	
  11/778315

  	
   

  	
  16-Jul-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  N-PR

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/118079

  	
   

  	
  26-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26-Nov-2009

  
	
  04-972

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/00510

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/26166

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/34322

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  L

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  PCT/US07/71685

  	
   

  	
  20-Jun-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  N-WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  PCT/US09/65925

  	
   

  	
  25-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C13

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/05308

  	
   

  	
  7-Jan-2005

  	
   

  	
  2006/05308

  	
   

  	
  31-Oct-2007

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2008/01144

  	
   

  	
  31-Aug-2006

  	
   

  	
  2008/01144

  	
   

  	
  28-Jan-2009

  	
   

  	
  31-Aug-2026

  

 

 

	
  Title

  	
   

  	
  Novel Enantiomeric Compounds For Treatment Of Cardiac Arrhythmia And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-975

  	
   

  	
  D

  	
   

  	
  AR

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  P000105424

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-AT

  	
   

  	
  AT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  10912/01

  	
   

  	
  13-Oct-2000

  	
   

  	
  774873

  	
   

  	
  21-Oct-2004

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-BE

  	
   

  	
  BE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2392016

  	
   

  	
  13-Oct-2000

  	
   

  	
  2392016

  	
   

  	
  13-Apr-2010

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C2-DIV

  	
   

  	
  CA

  	
   

  	
  DIV

  	
   

  	
  Closed

  	
   

  	
  tbd

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-CH

  	
   

  	
  CH

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-CY

  	
   

  	
  CY

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-DE

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  60035888.7

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-DK

  	
   

  	
  DK

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C7

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  7011241.2

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-ES

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-FI

  	
   

  	
  FI

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-FR

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-GB

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-GR

  	
   

  	
  GR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C6

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Granted

  	
   

  	
  3100473.3

  	
   

  	
  3-Dec-2007

  	
   

  	
  1049829

  	
   

  	
  22-Feb-2008

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C7-HK

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Published

  	
   

  	
  8101920.5

  	
   

  	
  22-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-IE

  	
   

  	
  IE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-IT

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C5

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2001-531818

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-LU

  	
   

  	
  LU

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-MC

  	
   

  	
  MC

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-NL

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-PT

  	
   

  	
  PT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-SE

  	
   

  	
  SE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  10/989010

  	
   

  	
  15-Nov-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/680873

  	
   

  	
  6-Oct-2000

  	
   

  	
  6372783

  	
   

  	
  16-Apr-2002

  	
   

  	
  6-Oct-2020

  
	
  04-975

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/684046

  	
   

  	
  6-Oct-2000

  	
   

  	
  6362223

  	
   

  	
  26-Mar-2003

  	
   

  	
  6-Oct-2020

  
	
  04-975

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/123573

  	
   

  	
  15-Apr-2002

  	
   

  	
  6683195

  	
   

  	
  27-Jan-2004

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/697683

  	
   

  	
  29-Oct-2003

  	
   

  	
  6818782

  	
   

  	
  16-Nov-2004

  	
   

  	
  15-Apr-2022

  
	
  04-975

  	
   

  	
  PRO1

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/159609

  	
   

  	
  15-Oct-1999

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Oct-2000

  
	
  04-975

  	
   

  	
  PRO2

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/290089

  	
   

  	
  10-May-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-May-2002

  
	
  04-975

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US00/28636

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  Title

  	
   

  	
  Novel Long-Acting Local Anesthetics

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-996

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/093018

  	
   

  	
  16-Jul-1998

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16-Jul-1999

  
	
  04-996

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/356283

  	
   

  	
  16-Jul-1999

  	
   

  	
  6114344

  	
   

  	
  5-Sep-2000

  	
   

  	
  16-Jul-2019

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  05-611

  	
   

  	
  EP-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  E446300

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2006270086

  	
   

  	
  11-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0613047-0

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2612599

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6.02006E+11

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-EP-D1

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  9012534.5

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  2334712

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  3070959

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  8113439.4

  	
   

  	
  10-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  187917

  	
   

  	
  5-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  76/KOLNP/2008

  	
   

  	
  4-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-521686

  	
   

  	
  11-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-7031026

  	
   

  	
  31-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  MX/a/2008/000497

  	
   

  	
  10-Jan-2008

  	
   

  	
  272977

  	
   

  	
  18-Dec-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-NO

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20080828

  	
   

  	
  15-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2007-502821

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  

 

 

 

	
  05-611

  	
   

  	
  WO-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008105757

  	
   

  	
  14-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/699780

  	
   

  	
  15-Jul-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Jul-2006

  
	
  05-611

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/457719

  	
   

  	
  14-Jul-2006

  	
   

  	
  7498449

  	
   

  	
  3-Mar-2009

  	
   

  	
  9-Feb-2027

  
	
  05-611

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/27599

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2007/10688

  	
   

  	
  14-Jul-2006

  	
   

  	
  2007/10688

  	
   

  	
  30-Sep-2009

  	
   

  	
  14-Jul-2026

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  DIBENZO [b,f][1,4]OXAZAPINE COMPOUNDS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  06-834

  	
   

  	
  WO-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008225014

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0808828-4

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2678897

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0088E+11

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  8732129.5

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  10103213.3

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  200250

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  4967/CHENP/2009

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009-553781

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  10-2009-7021464

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2009/009535

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2009-501530

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009138039

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  TW

  	
   

  	
  TW

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  97109258

  	
   

  	
  14-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/895046

  	
   

  	
  15-Mar-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Mar-2008

  
	
  06-834

  	
   

  	
  US

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  12/047858

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  PCT/US08/56866

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009/06573

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  A Dispersion-Capped Polarizable Force Field For Hydrocarbons

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  07-302

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/910363

  	
   

  	
  5-Apr-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Apr-2008

  

 

 

	
  Title

  	
   

  	
  Utility of Genotyping in the First Evaluation of a Novel Vitamin K Antagonist

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  08-026

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  61/019457

  	
   

  	
  7-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2009

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Agonists of Peroxisome Proliferator Activated Receptor-Alpha

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  08-528

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/139012

  	
   

  	
  19-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Dec-2009

  
	
  08-528

  	
   

  	
  PR2

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/139016

  	
   

  	
  19-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Dec-2009

  
	
  08-528

  	
   

  	
  PR3

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/287892

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Dec-2010

  
	
  08-528

  	
   

  	
  US

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Pending

  	
   

  	
  12/641954

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  08-528

  	
   

  	
  WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  PCT/US09/68763

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Treating Atrial Fibrillation And Reducing Stroke Rate In Atrial Fibrillation Patients

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1219

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263465

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Stroke Reduction In Atrial Fibrillation Patients

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1220

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263564

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Treating Atrial Fibrillation

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1221

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263567

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  

 

 

	
  Title

  	
   

  	
  Deuterium-Enriched Antiarrhythmic Compounds And
  Compositions

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-670

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/184582

  	
   

  	
  5-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  D2 Antagonists, Methods of Synthesis and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-698

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/187971

  	
   

  	
  17-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Localized Delivery of 5HT4 Agonists

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-734

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/220798

  	
   

  	
  26-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Compounds For Treatment of Cardiac Arrhythmia, Synthesis
  And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-949

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/242032

  	
   

  	
  14-Sep-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14-Sep-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  D2 Antagonists, Methods Of Synthesis And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  10-776

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/356096

  	
   

  	
  18-Jun-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jun-2011

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Localized Delivery Of 5HT4 Agonists

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  10-777

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/359435

  	
   

  	
  29-Jun-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29-Jun-2011

  

 

 

Exhibit C

 

U.S.
TRADEMARKS AND TRADEMARK APPLICATIONS

 

(List
marks below or indicate “None”)

 

	
  Registration
  No.

  	
   

  	
  Pending

  Application No.

  	
   

  	
  Mark

  	
   

  	
  Registration Date

  	
   

  	
  Filing Date

  
	
  None

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

UNREGISTERED
TRADEMARKS: List marks below or indicate “None.”

 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]